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This is NOT a clinical guideline. The suggestions for practice outlined represent 
professional opinion only.
Introduction:
At the time of writing, 51,608 people have tested positive for COVID-19 in the UK in less than three 
months; 5,373 have died. (1)  These figures will have risen by the time you read this. Around 5% (2)2 
of COVID-19 infections appear to require intensive care unit (ICU) admission. As the number of 
people contracting the illness increases rapidly, so does ICU clinical experience. Hundreds of 
intensivists will by now have had to manage multiple complex COVID-19 patients. 
A variety of guidelines have been rapidly produced (e.g. NICE guidance on critical care escalation (3),  
Surviving Sepsis guidelines (4) and more), and NHS England with the Faculty of Intensive Care 
Medicine plan release of UK management guidelines shortly. However, solid data upon which to 
base these are sparse. As a result, optimal management depends on rapid dissemination of 
experiential learning.
To address this need, the Intensive Care Society held a webinar on April 3rd 2020 at which 
representatives from 11 of the most COVID-19 experienced hospital trusts in England & Wales 
shared learning around 5 specific topic areas in an open forum. Further webinars will be arranged 
over the next few weeks. Details can be obtained from info@ics.ac.uk ([subject] Knowledge-sharing). 
This paper summarises the emerging learning and practice shared by those frontline clinicians.  It 
represents their professional opinions and should not be used as a clinical guideline document. Key 
emerging knowledge and suggestions for practice are presented in bold. Bullets in italics outline 
modifications to clinical practice made by individual trusts.
1. Covid-19 underlying patho-physiology & presentation of respiratory failure
 Covid-19 appears to have several phases (5). Management should be guided by timing 
of presentation in relation to the onset of symptoms to understand where in the 
trajectory of the disease the patient is.  
 Early phase respiratory failure seems predominantly due to impaired 
pulmonary perfusion. Pro-coagulation leading to micro-vascular pulmonary 
thrombosis has been observed. Lung compliance is generally good.  
 Later respiratory failure can involve ARDS and bacterial pneumonia
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2. Mechanical Ventilation
 Aggressive ventilation in the early phase may adversely affect later outcomes. Starting 
positive end-expiratory pressure (PEEP) should be lower than previously 
recommended. PEEP 10cm H2O or less appears satisfactory for many: higher PEEP can 
impair pulmonary perfusion, and gains in oxygenation are often limited. CO2 clearance 
is often not greatly improved by aggressive ventilation, given the high shunt fraction/ 
increase in physiological deadspace which is a core driver.
 Consider early proning of patients to improve VQ matching. 
Examples of clinical practice:
o proning on admission to ICU if in early phase (predominantly perfusion) disease. It can be 
done irrespective of PF ratio, and if response is positive, this may avoid aggressive 
ventilation.
o using cut off PF ratio =<16 for proning
o using ‘proning teams’ to manage turning, utilising non-ICU staff from around the hospital
 Pulmonary vasodilatation may provide short-term benefit. 
Examples of clinical practice:
o Using nitric oxide in early stages – it can help but may become refractory after 96 hours 
or so
o Using nebulised or IV prostacyclin – this may be helpful as part of therapeutic trial, if you 
are using wet ventilation circuits
 Cast formation and plugging can affect dry circuits: wet circuits may be beneficial. 
Examples of clinical practice:
o Using wet circuits for all-Covid areas where full personal protective equipment is in use
o Using checklists to monitor HMEs e.g. 12-hourly as these can fill with water rapidly – this 
is important in context of reduced nursing ratio. Routinely change every 24 hours in any 
event if not needing a change before that.
o Use of mucolytics (e.g. N-acetyl cysteine) may be considered.
o Managing patients on anaesthetic machines with higher flow rates may help limit need 
for soda lime changes (but beware total O2 use limitations), zoning the machines 
together, educating nursing staff on use of the machines, asking anaesthetists familiar 
with machines to support, transferring patients out for weaning
 Severe upper airway swelling in some patients may make extubation difficult.
Examples of clinical practice:
o Using dexamethasone prior to extubation, having nebulised adrenaline available, with 
surgical airway expertise (e.g. ENT) on site and on standby.
o Cohorting patients ready for extubation to areas with relevant expertise and extubation 
protocols
o A mobile airway team might be an alternative
 Re-intubation rates within 24-48 hours seem higher than expected (up to 60%) so 
delaying initial extubation for longer than usual may be sensible.
o Examples of clinical practice
o Waiting 48 hours past fever resolution and monitoring the inflammatory markers to 
ensure hyperinflammatory state is improving before attempted extubation
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3. Antibiotics
 Antibiotic usage should be judicious. There are some reports of later aspergillosis and 
candida infections.   
Examples of clinical practice:
o Stopping antibiotics in Covid patients unless clearly indicated, using procalcitonin (PCT) 
and other inflammatory markers to monitor for bacterial infection and restarting as 
required* 
o Using procalcitonin as a ‘stop’ signal to guide when to stop antibiotic use*
*False negative PCTs seem less of an issue than false positives in determining antibiotic use - 
anecdotally, rising procalcitonin has been seen in patients without evidence of bacterial 
infection, perhaps in relation to ‘cytokine storm’, and so a low PCT may be more helpful (true 
negative) than a high PCT (false positive) 
4. Fluid Balance & Renal Support
 Profound pyrexia, followed by use of CPAP, may mean that patients are dehydrated.
 Careful use of fluids aiming for euvolaemia may be beneficial in early phase disease - 
provided that the ventilation effort is well controlled to avoid oedema – as perfusion is 
a problem and prior to intensive care patients tend to have been dry.
 Renal injury has been more common in UK cases than anticipated (20-35% of ICU 
patients). Careful attention to adequate hydration, and use of lower PEEP, may help.
 Consider commencing therapeutic anticoagulation prior to haemofiltration, as filter life 
appears very short in its absence. 
Examples of clinical practice: 
o Using systemic unfractionated or treatment dose low molecular weight heparin and using 
aPTT and anti-factor Xa levels for monitoring
o Close partnership with renal team to manage resources
o Using shorter sharper diafiltrating to service machines to more than 1 person & manage 
filter supply
5. Workforce & Infection Control
 Ensure staff are comfortable in their Personal Protective Equipment (PPE).
Example of clinical practice:
o Buddying for donning & doffing, potentially using medical students to observe & confirm 
effective practice
 Promote effective use of the Teams model (e.g. for resus, intubation, proning).  
Example of clinical practice:
o Developing standard operating procedures for tasks for helpers.  Resources are available 
including the NHS England website & BACCN which are updated daily and can be adapted 
for local use
 Beware of ‘cognitive overload’ which can detract from getting basic ITU care right. 
Example of clinical practice:
o Having a tactical commander on site so the clinical leads can focus on clinical tasks & 
provide support to the nursing and allied staff  
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